ITGAV

Across TCGA pan-cancer cohorts, ITGAV mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ITGAV data layer compared with 26 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ITGAV mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ITGAV expression acts as an unfavorable survival marker.

CCRCC, PDAC, and LSCC are the cancer types where ITGAV mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.139	0.979	.001	45	view →
PDAC	DFS	Quartile	All	0.274	0.601	.001	27	view →
LSCC	OS	Tertile	II,III,IV	0.643	0.951	.011	20	view →
LUAD	OS	Median	II,III,IV	0.507	0.893	.046	3	view →
GBM	OS	Quartile	All	0.541	0.902	.020	2	view →
HNSC	OS	Median	IV	0.639	0.832	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ITGAV–CCRCC (DFS)

Open the CCRCC breakdown →